Kathryn Schnippel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7543365/publications.pdf

Version: 2024-02-01

47 papers	1,744 citations	430874 18 h-index	276875 41 g-index
48 all docs	48 docs citations	48 times ranked	2221 citing authors

#	Article	IF	Citations
1	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
2	Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respiratory Medicine,the, 2018, 6, 699-706.	10.7	189
3	Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 979-985.	1.2	129
4	The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE, 2012, 7, e36966.	2.5	126
5	High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. European Respiratory Journal, 2018, 52, 1801528.	6.7	92
6	Rapid Point-of-Care CD4 Testing at Mobile HIV Testing Sites to Increase Linkage to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e13-e17.	2.1	88
7	Scaling up Xpert MTB/RIF technology: the costs of laboratoryâ€•vs. clinicâ€based rollâ€out in South Africa. Tropical Medicine and International Health, 2012, 17, 1142-1151.	2.3	54
8	How to Estimate the Cost of Point-of-Care CD4 Testing in Program Settings: An Example Using the Alere Pimaâ„¢ Analyzer in South Africa. PLoS ONE, 2012, 7, e35444.	2.5	48
9	Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2017, 72, 1871-1879.	3.0	41
10	Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Tropical Medicine and International Health, 2013, 18, 109-116.	2.3	40
11	Point-of-care XpertÂ® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. International Journal of Tuberculosis and Lung Disease, 2013, 17, 368-372.	1.2	32
12	Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. International Journal of Infectious Diseases, 2015, 39, 89-94.	3.3	31
13	Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough. AIDS Research and Treatment, 2013, 2013, 1-7.	0.7	30
14	Diagnosing Xpert MTB/RIF negative TB: Impact and cost of alternative algorithms for South Africa. South African Medical Journal, 2013, 103, 101.	0.6	27
15	Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Services Research, 2018, 18, 973.	2.2	26
16	Estimating Implementation and Operational Costs of an Integrated Tiered CD4 Service including Laboratory and Point of Care Testing in a Remote Health District in South Africa. PLoS ONE, 2014, 9, e115420.	2.5	25
17	Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infectious Diseases, 2016, 16, 593.	2.9	23
18	Delays, interruptions, and losses from prevention of mother-to-child transmission of HIV services during antenatal care in Johannesburg, South Africa: a cohort analysis. BMC Infectious Diseases, 2015, 15, 46.	2.9	21

#	Article	IF	Citations
19	The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health and Quality of Life Outcomes, 2019, 17, 94.	2.4	20
20	Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Applied Health Economics and Health Policy, 2018, 16, 43-54.	2.1	17
21	Cost Evaluation of Reproductive and Primary Health Care Mobile Service Delivery for Women in Two Rural Districts in South Africa. PLoS ONE, 2015, 10, e0119236.	2.5	16
22	Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1106-1111.	1.2	14
23	Delay to diagnosis and breast cancer stage in an urban South African breast clinic. South African Medical Journal, 2019, 109, 159.	0.6	14
24	Nonfatal Firearm Injuries by Intent in the United States: 2016-2018 Hospital Discharge Records from the Healthcare Cost and Utilization Project. Western Journal of Emergency Medicine, 2021, 22, 462-470.	1.1	14
25	Male Breast Cancer Has Limited Effect on Survivorâ€™s Perceptions of Their Own Masculinity. American Journal of Men's Health, 2017, 11, 246-252.	1.6	13
26	Choropleth Mapping of Cervical Cancer Screening in South Africa Using Healthcare Facility-level Data from the National Laboratory Network. AIMS Public Health, 2016, 3, 849-862.	2.6	13
27	Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS ONE, 2016, 11, e0164974.	2.5	12
28	Outcomes of treatment of drug-susceptible tuberculosis at public sector primary healthcare clinics in Johannesburg, South Africa: A retrospective cohort study. South African Medical Journal, 2016, 106, 1002.	0.6	11
29	Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/Î¼l using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa. PLoS ONE, 2017, 12, e0171675.	2.5	11
30	Discordant rifampicin susceptibility results are associated with XpertÂ® MTB/RIF probe B and probe binding delay. International Journal of Tuberculosis and Lung Disease, 2019, 23, 358-362.	1.2	11
31	Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1040-1045.	1.2	10
32	Fear of Treatments Surpasses Demographic and Socioeconomic Factors in Affecting Patients With Breast Cancer in Urban South Africa. Journal of Global Oncology, 2017, 3, 125-134.	0.5	10
33	Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 918-925.	1.2	10
34	Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. International Journal of Tuberculosis and Lung Disease, 2018, 22, 393-398.	1.2	10
35	Prospective One Year Follow Up of HIV Infected Women Screened for Cervical Cancer Using Visual Inspection with Acetic Acid, Cytology and Human Papillomavirus Testing in Johannesburg South Africa. PLoS ONE, 2016, 11, e0144905.	2.5	9
36	Cost-effectiveness of using the Cervex-Brush (broom) compared to the elongated spatula for collection of conventional cervical cytology samples within a high-burden HIV setting: a model-based analysis. BMC Health Services Research, 2015, 15, 499.	2.2	8

#	Article	IF	Citations
37	Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLoS ONE, 2017, 12, e0181238.	2.5	7
38	Missed appointments among rifampicin-resistant tuberculosis (RR-TB) patients at a decentralised RR-TB outpatient clinic in Johannesburg, South Africa. South African Medical Journal, 2016, 106, 912.	0.6	6
39	A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. South African Medical Journal, 2016, 106, 333.	0.6	6
40	Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals. PLoS ONE, 2017, 12, e0182154.	2.5	5
41	Age Differences by Sex in Antiretroviral-NaÃ¯ve Participants: Pooled Analysis from Randomized Clinical Trials. Journal of the Association of Nurses in AIDS Care, 2018, 29, 371-382.	1.0	5
42	The Effect of Access to Information on Beliefs Surrounding Breast Cancer in South Africa. Journal of Cancer Education, 2018, 33, 806-813.	1.3	5
43	A Data-Driven Evaluation of the Stop TB Global Partnership Strategy of Targeting Key Populations at Greater Risk for Tuberculosis. PLoS ONE, 2016, 11, e0163083.	2.5	5
44	Unraveling the South African Breast Cancer Story: The Relationship of Patients, Delay to Diagnosis, and Tumor Biology With Stage at Presentation in an Urban Setting. Journal of Surgical Research, 2019, 235, 181-189.	1.6	3
45	Impact and cost of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. South African Medical Journal, 2013, 103, 436.	0.6	2
46	Compliance to HIV treatment monitoring guidelines can reduce laboratory costs. Southern African Journal of HIV Medicine, 2016, 17, 449.	0.9	2
47	Breast abnormalities in adolescents receiving antiretroviral therapy. Southern African Journal of HIV Medicine, 2019, 20, 1017.	0.9	1